Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Results View source PDF Explain this filing

MEDPLUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.6%Reaction day

₹911.00

prior close

₹907.10

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)+0.4%+1.2% vs market

Retailing peers, median of 53sector · industry level+0.0%+1.6% vs sector

On the reaction day the stock moved 1.2 pts more than Nifty Microcap 250 and 1.6 pts more than its Retailing peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.2

10m

+2.0

15m

+2.0

30m

+2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.6+0.4+1.2+0.0+1.6

Next day

+0.6+0.8-0.1+0.3+0.3

-1.0+0.2-1.2-0.8-0.2

-0.7+0.0-0.7-1.1+0.4

-0.7-0.0-0.7-1.0+0.3

-2.7-0.3-2.5-1.0-1.8

-0.8-2.4+1.7-2.0+1.3

15d

-9.3-5.0-4.3-3.9-5.4

-8.5-4.6-4.0-2.9-5.6

-8.3-2.0-6.4+0.7-9.0

-16.0-4.4-11.7-3.8-12.3

UpDownMarket · Nifty Microcap 250Sector · Retailing peers, median of 53Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Medplus Health Services informed exchanges that its subsidiary Optival Health Solutions received three drug license suspension orders from Drug Control Administration authorities in Karnataka and Telangana. The suspensions affect stores at Basavanguli-Rathnavilas road (Karnataka, 3 days), West Marredpally Secundrabad (Telangana, 7 days), and Satyanarayana Colony Shameerpet (Telangana, 3 days). The orders were received on July 14, 2025, under Rule 65 of the Drugs and Cosmetics Act, 1940. Total potential revenue loss across all three stores is approximately Rs 3.88 lakhs, which is negligible relative to the company's overall operations.

Likely market impact

The financial impact is minimal at around Rs 3.88 lakhs in potential revenue loss across just three stores out of Medplus's large network. This is a routine regulatory compliance matter with no meaningful effect on shareholders or stock price.